Status:
ACTIVE_NOT_RECRUITING
Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis (EVOLVE)
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
University of California, San Francisco
Tulane University
Conditions:
Rheumatic Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
While tele-rheumatology (TR) visits are a COVID-19 related necessity, there is a lack of rigorous data on the comparative effectiveness of TR versus (vs) in-person usual care (UC) especially in medica...
Detailed Description
People with RMDs, especially those with multi-comorbidities and on IS are among the most at-risk for COVID-19-related fragmented care and poor outcomes. RMD burden is high in terms of disability-adjus...
Eligibility Criteria
Inclusion
- Diagnosis of rheumatic disease (e.g. rheumatoid arthritis, SLE)
Exclusion
- unstable rheumatic disease that needs in-person visits (e.g. recent diagnosis of severe lupus nephritis)
- expected in-office procedures (e.g., joint injection)
- lack of access to phone
Key Trial Info
Start Date :
September 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
652 Patients enrolled
Trial Details
Trial ID
NCT04704544
Start Date
September 15 2021
End Date
December 31 2025
Last Update
December 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294